Warby Parker Inc. (WRBY): EBITDA
$44.94M
Year ended 2025-12-31
$55.02M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $44.94M | +185.3% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $15.75M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$33.44M | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$79.34M | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | -$122.11M | n/m | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | -$37.87M | n/c | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $12.85M | n/a | 2022-03-18, From 2019-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Warby Parker Inc. (WRBY) | 2025-12-31 | $44.94M | +185.3% |
| National Vision Holdings, Inc. (EYE) | 2026-01-03 | $149.98M | +85.2% |
| Cooper Companies, Inc. (COO) | 2025-10-31 | $1.06B | -1.9% |
| Bausch & Lomb Corp (BLCO) | 2025-12-31 | $534.00M | -10.7% |
| RxSight, Inc. (RXST) | 2025-12-31 | -$44.92M | n/m |
Compare WRBY, EYE, COO, BLCO side by side · Screen every company in Ophthalmic Goods ↗